Studies have reported detrusor mastocytosis in patients with interstitial cystitis. The author describes a patient with systemic mastocytosis who was confirmed to have detrusor mastocytosis and interstitial cystitis. She responded to therapy with pentosanpolysulfate. The literature on systemic mastocytosis and the role of mast cells in the pathophysiology of interstitial cystitis are reviewed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00192-006-0266-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Revealing distinct treatment mechanisms and outcome correlations in patients with interstitial cystitis/bladder pain syndrome after different bladder therapies through urinary biomarker analysis.
Int Urol Nephrol
January 2025
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan.
Purpose: Urinary cytokine changes may serve as biomarkers to assess treatment outcomes for interstitial cystitis/bladder pain syndrome (IC/BPS). This study analyzed the changes in urinary cytokines following various bladder therapies and explored their clinical significance in therapeutic mechanisms.
Methods: A total of 122 patients with IC/BPS treated with platelet-rich plasma (PRP), botulinum toxin-A (BoTN-A), hyaluronic acid (HA), or low-energy shock wave (LESW) were evaluated.
Sentiments of Individuals with Interstitial Cystitis/Bladder Pain Syndrome Toward Pentosan Polysulfate Sodium: Infodemiology Study.
JMIR Form Res
January 2025
Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, United States.
Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a multifactorial, chronic syndrome involving urinary frequency, urgency, and bladder discomfort. These IC/BPS symptoms can significantly impact individuals' quality of life, affecting their mental, physical, sexual, and financial well-being. Individuals sometimes rely on peer-to-peer support to understand the disease and find methods of alleviating symptoms.
View Article and Find Full Text PDFDevelopment of a unique crosslinked glycosaminoglycan for soft tissue repair: Treatment of interstitial cystitis/bladder pain syndrome.
PLoS One
January 2025
Glycologix, Inc., 100 Cummings Center, Beverly, Massachusetts, United States of America.
Chemical modification of naturally derived glycosaminoglycans (GAGs) expands their potential utility for applications in soft tissue repair and regenerative medicine. Here we report the preparation of a novel crosslinked chondroitin sulfate (~200 to 2000 kilodaltons) that is both soluble in aqueous solution and microfilterable. We refer to these materials as "SuperGAGs.
View Article and Find Full Text PDFRepeated intravesical injections of platelet-rich plasma are safe and effective in the treatment of interstitial cystitis/bladder pain syndrome.
Tzu Chi Med J
October 2024
Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.
Objectives: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a challenging chronic inflammatory condition affecting the urinary bladder, with limited treatment options. This study aims to assess the clinical efficacy of repeated intravesical platelet-rich plasma (PRP) injections for promoting urothelial regeneration and reducing inflammation in patients with IC/BPS and investigate its correlation with subjective and objective treatment-related outcomes.
Materials And Methods: Four monthly intravesical PRP injections were given to 98 patients with non-Hunner-type IC/BPS.
Comparison of the Abbott Alinity m and Qiagen Artus assays for the quantification of BK virus in clinical samples.
IJID Reg
March 2025
Virology Department, Hôpital Paul Brousse, INSERM U1193, AP-HP, Université Paris Saclay, Paris, France.
Objectives: BK virus (BKV) is highly seroprevalent in humans. After primary infection, it remains latent in the urinary tract and can reactivate in immunocompromised individuals, leading to interstitial nephropathy or hemorrhagic cystitis. The BKV viral load (VL) in plasma correlates with the occurrence of nephropathy and can be monitored in kidney graft recipients; the early detection of BKV viremia can enable an early reduction of immunosuppressant drug doses and the prevention of BKV-associated nephropathy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!